PDCD1 and non-small cell lung carcinoma: Based on these observations and the importance of adaptive immunity for generating long-term responses, we decided to combine RMC-4998 and RMC-4550 with anti-PD-1 ICB therapy, an established immunotherapy option for NSCLC patients.